Semaglutide Dosage in Units: How to Convert Mg to Units

Semaglutide is prescribed in milligrams, not in the “units” marked on insulin syringes, and confusing the two measurement systems is one of the most common and dangerous dosing errors reported with this drug. Brand-name prefilled pens (Ozempic, Wegovy, Rybelsus) are designed to deliver a fixed milligram dose with each injection or tablet, effectively removing the need for patients to calculate anything. The confusion around “semaglutide dosage in units” almost always traces back to compounded versions of the drug, which arrive in multi-dose vials and require patients to draw up doses using syringes calibrated in units or milliliters rather than milligrams. Understanding how the dosing actually works, and where the pitfalls hide, matters for anyone starting or switching between formulations.

Why “Units” and “Milligrams” Are Not the Same Thing

Insulin syringes are marked in “units,” a measurement specific to insulin’s biological potency. One unit of insulin is not one milligram of insulin. When people use those same syringes to draw up compounded semaglutide from a vial, the markings on the syringe no longer correspond to the drug’s actual dose. A case series reported to a poison control center documented patients who made tenfold dosing errors with compounded semaglutide, experiencing days of nausea, vomiting, and abdominal pain as a result. One patient specifically reported dosing in milliliters and units rather than milligrams, and the investigators noted that vials of compounded semaglutide lack the safety features of prefilled manufactured pens, allowing large overdoses to happen easily.¹

The root of the problem is that compounded semaglutide vials come in varying concentrations. A vial labeled “5 mg/mL” requires a very different volume than one labeled “2.5 mg/mL” to deliver the same milligram dose. If you then try to translate that volume into the “unit” markings on an insulin syringe, you are doing mental math across three different measurement systems: milligrams (what your doctor prescribed), milliliters (how volume is measured), and units (what the syringe displays). Each conversion is a chance for error, and no standardized conversion chart exists because compounding pharmacies use different concentrations.

How Prefilled Pens Eliminate the Problem

Brand-name semaglutide for diabetes (Ozempic) and for weight management (Wegovy) ships in prefilled pen injectors. For the diabetes indication, single-dose pen injectors were developed for each of the three approved subcutaneous dose levels: 0.25 mg, 0.5 mg, and 1.0 mg.² You do not select a dose, dial a number, or draw anything from a vial. You press the pen against your skin, it activates, and it delivers the labeled milligram amount. There is no opportunity to accidentally give yourself ten times the intended dose.

Wegovy pens work on a similar principle but cover the weight-management dose range, which tops out at 2.4 mg per week. The Ozempic multi-dose pen does require you to dial a dose, but the dial is labeled in milligrams (0.25 or 0.5 on one pen, 1.0 on another), not in units. The device physically prevents you from dialing beyond its maximum. This engineering is deliberate: the pen’s entire purpose is to keep measurement errors from reaching the patient.

The Standard Dose Schedules

Semaglutide dosing follows a gradual escalation pattern regardless of indication. The escalation exists because higher doses cause more gastrointestinal side effects, particularly nausea, and ramping up slowly gives the body time to adapt.³

For type 2 diabetes (Ozempic), the escalation looks like this:

Weeks 1–4: 0.25 mg once weekly (starter dose, mainly for tolerability)
Week 5 onward: 0.5 mg once weekly
If needed: 1.0 mg once weekly after at least four weeks on 0.5 mg
Maximum: 2.0 mg once weekly, though this higher dose was added later and may not be available everywhere

For weight management (Wegovy), escalation takes longer because the target dose is higher:

Weeks 1–4: 0.25 mg once weekly
Weeks 5–8: 0.5 mg once weekly
Weeks 9–12: 1.0 mg once weekly
Weeks 13–16: 1.7 mg once weekly
Week 17 onward: 2.4 mg once weekly (maintenance dose)

Clinical trials for weight management assessed semaglutide at 2.4 mg per week against the 1.0 mg dose approved for diabetes, and 2.4 mg delivered substantially more weight loss.⁴ Each step in the escalation is meant to last at least four weeks, and some prescribers hold patients at intermediate doses longer if side effects are bothersome.

Why More Drug Does Not Always Mean Proportionally More Effect

A common assumption is that doubling the dose doubles the benefit. With semaglutide, that is not how it works. Exposure-response analyses in people with type 2 diabetes found that blood sugar reductions followed a curve that flattened at higher concentrations. The half-maximum effect on HbA1c was reached at a drug concentration of about 6.5 nmol/L, which corresponds roughly to the 0.5 mg dose range. The 1.0 mg dose produced consistently better blood sugar and weight outcomes than 0.5 mg, but the incremental gains shrank as exposure climbed.⁵

Model-based analyses comparing semaglutide with other drugs in the same class confirm this pattern: both agents showed nonlinear dose-response relationships, with the incremental benefit tapering off at higher doses.⁶ This diminishing-returns curve is worth understanding because it means that skipping escalation steps to “get to the good dose faster” buys you proportionally less extra benefit while exposing you to the full brunt of side effects your body has not adapted to. The escalation schedule is designed to ride this curve efficiently.

Oral Semaglutide Uses Completely Different Numbers

Rybelsus is oral semaglutide, taken as a daily tablet, and its doses are in a different ballpark: 3 mg, 7 mg, and 14 mg. Those numbers look dramatically larger than the 0.25–2.4 mg range for injections, and that difference catches people off guard. The reason is bioavailability. When you swallow a peptide drug, most of it gets destroyed in the gut before it ever reaches the bloodstream. Oral semaglutide uses a special absorption-enhancing compound (SNAC) that protects it from enzymatic breakdown and helps it pass through the stomach lining, but even with that technology, the amount of drug that actually makes it into circulation is much lower and more variable than with an injection.⁷

So you need a higher milligram dose in the tablet to achieve blood levels comparable to what a much smaller injected dose delivers. The oral 14 mg daily dose produces roughly similar glycemic effects to subcutaneous 0.5–1.0 mg weekly, not to 14 mg injected. This is another area where confusing the numbers across formulations could cause real trouble. Switching between oral and injectable semaglutide is not a matter of matching the milligram numbers; it requires a prescriber to select the appropriate dose for each route independently.

What Happens When You Miss Doses or Need to Restart

Semaglutide has a half-life of about one week, which is why it works as a once-weekly injection.⁸ The drug accumulates in your system over the first four to five weeks, then reaches a steady state where the amount going in each week roughly equals the amount being cleared. Missing a single dose is typically manageable: the drug level dips but does not crash. The standard guidance is to take the missed dose within five days of the scheduled day, then resume your normal schedule. If more than five days have passed, skip the missed dose and take the next one as planned.

Longer gaps are more consequential. When someone misses three or more consecutive weekly doses, restarting at the full maintenance dose can provoke severe nausea and vomiting because the body has lost its adaptation. A case report documented an adverse event following GLP-1 receptor agonist reinitiation after a prolonged lapse, and the investigators recommended that patients who have missed three or more doses should restart at a reduced dose, tailored to how long the break lasted and how well they tolerated the drug previously.⁹ In practice, many prescribers have patients re-escalate through at least a few of the lower doses rather than jumping straight back to their maintenance level, especially if the gap was a month or more.

Alternative Dosing Intervals and the Cost Question

Semaglutide is expensive, and insurance coverage is inconsistent, particularly for the weight-management indication. That has driven interest in whether the drug can be stretched further than once a week. Pharmacokinetic modeling suggests the answer is a qualified yes. One analysis found that giving 2.4 mg every two weeks instead of every week cut the total drug used by half but preserved about 72% of the weight loss, with the model predicting roughly 12% body weight reduction at the two-week interval versus 17% at the standard weekly interval.¹⁰

This is not yet a clinically validated dosing strategy; it comes from mathematical modeling rather than randomized trials in patients. But the principle tracks with what we know about the drug’s long half-life: because semaglutide clears slowly, extending the interval does not cause the abrupt peaks and valleys you would see with a short-acting drug. The clinical implications are still being worked out, and no regulatory body has approved an every-other-week regimen. But for patients who face supply shortages or coverage gaps, some clinicians have used extended intervals as a pragmatic bridge rather than stopping the drug entirely.

Do Kidney Problems Change the Dose?

Many people taking semaglutide for type 2 diabetes also have some degree of kidney impairment, so the question of whether the dose needs adjustment in that population comes up often. A pharmacokinetic study that included people across the full spectrum of kidney function, from mild impairment to end-stage renal disease on hemodialysis, found that semaglutide exposure was not meaningfully affected by kidney impairment after adjusting for age, sex, and body weight. The investigators concluded that dose adjustment does not appear to be warranted for patients with impaired kidney function.¹¹ This is somewhat unusual for injectable medications, many of which do require lower doses when kidney clearance drops, so it is worth flagging for anyone who assumes their kidney issues automatically mean a dose change.

That said, the gastrointestinal side effects of semaglutide, particularly nausea and vomiting, can cause dehydration, and dehydration is harder on compromised kidneys. So while the drug itself does not need a dose cut, the side-effect management may need to be more aggressive. Clinicians sometimes escalate more slowly in these patients for exactly that reason.

Converting Between Compounded Semaglutide Concentrations

If you are using compounded semaglutide from a vial, the math you actually need is straightforward, but the stakes of getting it wrong are high. The key number is the concentration listed on the vial, expressed as milligrams per milliliter (mg/mL). If your vial is 5 mg/mL and your prescribed dose is 0.5 mg, you need to draw up 0.1 mL. On most insulin syringes, 0.1 mL corresponds to 10 “units” on the syringe barrel, because standard insulin syringes are calibrated so that 1 mL equals 100 “units.” But those “units” have nothing to do with the drug; they are just volume markings on that particular syringe.

Change the vial concentration to 2.5 mg/mL, and now 0.5 mg of semaglutide requires 0.2 mL, which reads as 20 “units” on the syringe. Same drug, same prescribed dose, different number on the syringe. If you had memorized “10 units” from a previous vial and applied it to the new one, you would get half the intended dose. Go the other direction, from a dilute vial to a concentrated one, and you could give yourself double. The poison control case series emphasized that the variability of dosing units across milliliters, units, and milligrams was a primary contributor to patient confusion and overdose events.¹²

Anyone using a compounded vial should have a dispensing pharmacist walk them through the calculation for their specific vial concentration and syringe type before the first injection. One of the patients in the poison control case series reported receiving a vial with syringes and no pharmacist counseling at all, which is a red flag for any compounding pharmacy. If you receive a vial without a clear, personalized explanation of how many milliliters or syringe markings correspond to your milligram dose, call the pharmacy before injecting anything.

How Semaglutide Compares to Newer Dual-Agonist Drugs on a Dose Basis

Newer drugs in the same therapeutic space, like tirzepatide (Mounjaro/Zepbound), work on a similar receptor but also hit a second target. Because of that dual mechanism, the milligram doses of these drugs are not interchangeable with semaglutide. A trial comparing a dual glucagon/GLP-1 receptor agonist with open-label semaglutide found that lower doses of the dual agonist produced HbA1c reductions similar to semaglutide 1.0 mg weekly, with one dose group achieving a mean HbA1c reduction of about 1.5 percentage points, closely matching semaglutide’s 1.47 percentage point reduction.¹³

The practical takeaway is that comparing milligram doses across different drugs in this class is meaningless. A “5 mg” dose of one medication and a “1.0 mg” dose of another can produce identical clinical effects because the drugs have different potencies, receptor affinities, and pharmacokinetic profiles. If you switch from semaglutide to tirzepatide or vice versa, the new dose is selected based on clinical response and tolerability guidelines, not by any mathematical conversion from one drug’s milligrams to another’s. This is yet another setting where thinking in “units” or trying to match numbers across products leads people astray.